The value of prognostic factors in small cell lung cancer: results from a randomised multicenter study with minimum 5 year follow-up

被引:146
作者
Bremnes, RM [1 ]
Sundstrom, S
Aasebo, U
Kaasa, S
Hatlevoll, R
Aamdal, S
机构
[1] Univ Tromso Hosp, Dept Oncol, N-9038 Tromso, Norway
[2] Univ Trondheim Hosp, Dept Oncol, N-7007 Trondheim, Norway
[3] Univ Tromso Hosp, Dept Pulm Med, N-9038 Tromso, Norway
[4] Norwegian Radium Hosp, Dept Oncol, N-310 Oslo, Norway
关键词
SCLC; limited disease; extensive disease; prognostic factors; survival;
D O I
10.1016/S0169-5002(02)00508-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We have evaluated the prognostic value of 22 pretreatment attributes in 436 small cell lung cancer (SCLC) patients included in a prospective multicenter study with a minimum 5-year follow-up. Pretreatment clinical and laboratory parameters were registered. Possible prognostic factors were evaluated by univariate analysis (log rank test) and by the Cox multivariate regression model. In the univariate analysis of all patients, only age, nodal metastasis, and skin metastasis were not associated with survival. The multivariate Cox model identified gender, extent of disease, performance status (PS), weight loss, platelet count, LDH, and NSE as independent prognostic factors. In subset multivariate analyses according to extent of disease, we found haemoglobin level, PS, NSE, and total WBC as significant prognostic indicators for survival in limited-stage disease (LD-SCLC), while PS, weight loss, LDH, number of metastases, liver metastases, and brain metastases were identified as independent prognostic factors in extensive-stage disease (EDSCLC). There was a significant correlation between serum LDH and NSE levels. In conclusion, gender, extent of disease, PS, weight loss, haemoglobin, WBC count, platelet count, LDH, and NSE were all found to be independent prognostic factors for SCLC survival. However, the prognostic value of these factors depends highly on whether all or subsets of SCLC patients are studied. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:303 / 313
页数:11
相关论文
共 45 条
[21]   New chemotherapy agents for small cell lung cancer [J].
Kelly, K .
CHEST, 2000, 117 (04) :156S-162S
[22]   Pretreatment prognostic factors for survival in small-cell lung cancer: A new prognostic index and validation of three known prognostic indices on 341 patients [J].
Maestu, I ;
Pastor, M ;
GomezCodina, J ;
Aparicio, J ;
Oltra, A ;
Herranz, C ;
Montalar, J ;
Munarriz, B ;
Reynes, G .
ANNALS OF ONCOLOGY, 1997, 8 (06) :547-553
[23]  
MAURER LH, 1981, CANCER TREAT REP, V65, P767
[24]  
OSTERLIND K, 1986, CANCER RES, V46, P4189
[25]   LDH or NSE or LDH and NSE as pretreatment prognostic factors in small cell lung cancer? A commentary [J].
Osterlind, K .
LUNG CANCER, 2000, 30 (01) :51-53
[26]  
Paesmans M, 2000, CANCER-AM CANCER SOC, V89, P523, DOI 10.1002/1097-0142(20000801)89:3<523::AID-CNCR7>3.0.CO
[27]  
2-6
[28]   A METAANALYSIS OF THORACIC RADIOTHERAPY FOR SMALL-CELL LUNG-CANCER [J].
PIGNON, JP ;
ARRIAGADA, R ;
IHDE, DC ;
JOHNSON, DH ;
PERRY, MC ;
SOUHAMI, RL ;
BRODIN, O ;
JOSS, RA ;
KIES, MS ;
LEBEAU, B ;
ONOSHI, T ;
OSTERLIND, K ;
TATTERSALL, MHN ;
WAGNER, H .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (23) :1618-1624
[29]   Comparative prognostic value of lactate dehydrogenase and neuron-specific enolase in small-cell lung cancer patients treated with platinum-based chemotherapy [J].
Quoix, E ;
Purohit, A ;
Faller-Beau, M ;
Moreau, L ;
Oster, JP ;
Pauli, G .
LUNG CANCER, 2000, 30 (02) :127-134
[30]   AN OVERVIEW OF PROGNOSTIC FACTORS IN SMALL-CELL LUNG-CANCER - A REPORT FROM THE SUBCOMMITTEE FOR THE MANAGEMENT OF LUNG-CANCER OF THE UNITED-KINGDOM COORDINATING COMMITTEE ON CANCER-RESEARCH [J].
RAWSON, NSB ;
PETO, J .
BRITISH JOURNAL OF CANCER, 1990, 61 (04) :597-604